FDA Approved: PEMAZYRE — Supplemental Application (Incyte Corporation)

View source ↗

Summary

FDA approved a supplemental application for Pemazyre (pemigatinib) filed by Incyte Corporation, indicating an update to the drug's labeling or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

SUPPL AP for PEMAZYRE (PEMIGATINIB)